Quantcast
Last updated on April 18, 2014 at 8:30 EDT

Latest Teriparatide Stories

2011-05-24 05:03:00

CAMBRIDGE, Mass. and ST. PAUL, Minn., May 24, 2011 /PRNewswire/ -- Radius Health, Inc. ("Radius") and 3M Drug Delivery Systems ("3M") today announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius' novel, proprietary PTHrP (parathyroid hormone-related protein) analog, for the treatment of osteoporosis. The BA058 Microneedle Patch will use 3M's patented Microstructured Transdermal System microneedle technology to administer BA058 through the...

2011-05-24 05:00:00

CAMBRIDGE, Mass., May 24, 2011 /PRNewswire/ -- Radius Health, Inc. ("Radius") today announced that the company has raised approximately $91 million in its third financing round, including $66 million in equity financing and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance LLC to a $25 million multi-draw term loan facility. Five new investors, including BB Biotech AG, Brookside Capital, Saints Capital, Nordic Bioscience ("Nordic"), and Ipsen Pharma SAS ("Ipsen")...

2011-03-17 15:15:00

INDIANAPOLIS, March 17, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients should not use the alcohol prep pads made by the Triad Group that are contained in the black starter kits for Forteo® [teriparatide (rDNA origin) injection] in the United States. The Triad Group is recalling the alcohol prep pads due to potential contamination with the bacteria, Bacillus cereus, which could result in life threatening infections, especially in...

2011-01-25 11:55:24

Recommendations provide diagnosis, treatment guidance for postmenopausal women The American Association of Clinical Endocrinologists (AACE) has released new medical guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Loyola physician Pauline Camacho, MD, was part of a committee that developed the guidelines to manage this major public health issue. These recommendations were developed to reduce the risk of osteoporosis-related fractures and improve the quality of life...

2010-10-19 17:04:53

A drug marketed to grow bone in osteoporosis patients also works to heal bone wounds in gum disease patients, a University of Michigan study suggests. "This new approach for the treatment of periodontal disease could allow us to rebuild some of the bone that is lost due to periodontal disease, which until this point has been very difficult to achieve," said Jill Bashutski, clinical assistant professor at the U-M School of Dentistry and first author on the study. "Current treatments to re-grow...

80bade0876dca47b498c6ccbe4a1d1d51
2010-10-17 08:55:00

Forteo, a drug produced by Eli Lilly and Co. and used for osteoporosis, has been found to be able to re-grow bone in jaws damaged by severe bone-destroying conditions called osteonecrosis and periodontitis, doctors reported on Saturday.The research suggests that the drug may drive growth in a damaged jaw, according to researchers.Forteo, known as teriparatide generically, cuts the risk of bone fractures by half in patients with thinning bones by stimulating the growth of new bone. But the...

2010-10-14 12:59:00

INDIANAPOLIS, Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada. In partnership with TransPharma Medical Ltd.,...

2010-06-01 16:21:00

SILVER SPRING, Md., June 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) Osteoporosis is a disease in which the bones become weak and are more likely to break. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80 percent of the people in the...

2010-03-15 13:07:22

For best results, patient selection, correct indications, optimal medical treatment needed, according to a study of nearly 1,500 patients over seven years TAMPA, Fla. -- Patient selection is key for vertebroplasty"”a minimally invasive treatment performed by interventional radiologists in individuals with painful osteoporotic vertebral compression fractures that fail to respond to conventional medical therapy"”to be effective and successful, according to a study of more than 1,500...

2010-03-04 10:21:00

WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug's effect on reduction of new hip fractures is the attribute that most influences U.S. and European surveyed primary care physicians' (PCPs') prescribing decisions in osteoporosis. Clinical data and the opinions of interviewed thought leaders indicate Eli Lilly's Forteo (in Europe the brand name is Forsteo) has...